WaveMan
WaveMan · Company
DYAI · Dyadic International Inc
> Search tickers & screens ⌘K
LIVE
← All companies

DYAI Dyadic International (DYAI) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001213809
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

What the filings say about DYAI

Insiders, 180 days
-$125.0K net sold
1 seller · 0% of sales under a 10b5-1 plan

Dyadic International insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, DYADIC INTERNATIONAL INC insiders sold a net $125.0K of stock across 18 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Francisco Trust under agreement dated February 28, 1996
SELL
2026-07-24 SEC
2,616
$3.2K
-62.8%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Jul 23, 2026.
  • The trade is 0.1% of the 3,280,272 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Insider Francisco Trust under agreement dated February 28, 1996 sold about $3.2K of DYAI on Jul 24, 2026.
Francisco Trust under agreement dated February 28, 1996
SELL
2026-07-24 SECtraded 2026-07-23
54,760
$71.3K
-62.8%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Jul 22, 2026.
  • The trade is 1.7% of the 3,282,888 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Insider Francisco Trust under agreement dated February 28, 1996 sold about $71.3K of DYAI on Jul 23, 2026, the largest insider sale at the company since 2024.
Francisco Trust under agreement dated February 28, 1996
SELL
2026-07-24 SECtraded 2026-07-22
38,016
$50.5K
-62.8%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Jan 7, 2025.
  • The trade is 1.1% of the 3,337,648 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Insider Francisco Trust under agreement dated February 28, 1996 sold about $50.5K of DYAI on Jul 22, 2026, the largest insider sale at the company since 2024.
Hazelton Joseph P
President and COO
BUY
2025-08-05 SECtraded 2025-08-01
26,000
$24.7K
-57.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 16.7% of the 155,340 shares held after it.
  • No other insider bought within 30 days.
Insider activity: President and COO Hazelton Joseph P bought about $24.7K of DYAI on Aug 1, 2025, the largest insider purchase at the company on our record.
Francisco Trust under agreement dated February 28, 1996
SELL
2026-07-06 SECtraded 2025-01-07
15,000
$30.2K
-60.4%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Jan 6, 2025.
  • The trade is 0.4% of the 3,375,664 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Insider Francisco Trust under agreement dated February 28, 1996 sold about $30.2K of DYAI on Jan 7, 2025.
18 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 13 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$125.0K over 180 days
-$125.0K of it by a 10%+ holder
more than 54% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-11.6% year over year
below 66% of Pharma & Biotech
Margin
-238.3% net margin
below 68% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
0.7% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 79% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch DYAI

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-64.4%12M
-68%-37%-6%+25%2025-102025-122026-022026-042026-062026-082026-10 2026-07-23 · Francisco Trust under agreement dated February 28, 1996 sold $71.3K2026-07-22 · Francisco Trust under agreement dated February 28, 1996 sold $50.5K2026-07-24 · Francisco Trust under agreement dated February 28, 1996 sold $3.2K2026-07-21 · Francisco Trust under agreement dated February 28, 1996 filed to sell $539.3K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns DYAI: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in DYAI

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

DYAI planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Francisco Trust under agreement dated February 28, 1996
Filed 2026-07-21
$539.3K
Executive pay vs shareholder return · Mark Emalfarb
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.0M
$518.5K
$448.2K
-24%
n/a
2024
$1.0M
$1.1M
$448.7K
-60%
n/a
2023
$1.0M
$1.1M
$424.9K
-70%
n/a
2022
$1.4M
-$435.9K
$466.0K
-77%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $125.0K sold by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

DYAI financials

Revenue growth
-11.6%
XBRL, annual
Net margin
-238.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.8M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-200.5%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
-103.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-208.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$3.1M$3.5M$2.9M$2.9M
Operating income-$7.2M-$5.9M-$8.2M-$10.2M
Net income-$7.4M-$5.8M-$6.8M-$9.7M
EPS (diluted)-0.23-0.20n/an/a
Operating cash flow-$5.7M-$4.0M-$6.7M-$8.1M
Cash$4.6M$6.5M$6.5M$5.8M
SEC XBRL, fiscal years, as known on 2026-10-28

DYAI Stock Sonar score 4/7 axes

Find similar shapesCompare

DYAI ranks highest on risk and compliance (56th percentile) and growth (34th), and lowest on profitability (16th), among Pharma & Biotech peers.

Profitability
16
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-103.9% · 23 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-208.1% · 10 pct, sector of 576
Growth
34
Inputs
  • Revenue growth, YoY-11.6% · 34 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
26
Inputs
  • Net Form 4 buying (codes P and S), 180d-$125K · 52 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Risk and compliance
56
Inputs
  • Short interest, % of float+0.7% · 83 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+15.2% · 29 pct, sector of 511
3 not measured: Financial health, Institutional and government, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

DYAI filings, in plain words

Are Dyadic International insiders buying or selling DYAI?

In the 180 days to 2026-10-28, Dyadic International insiders were net sellers, a net $125.0K across purchases and sales reported on Form 4, by 1 seller.

Read the full summary

In the 180 days to 2026-10-28, Dyadic International insiders were net sellers of DYAI, a net $125.0K across purchases and sales reported on Form 4 by 1 seller. Most of that figure, $125.0K, came from a holder of 10% or more rather than an officer or director. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies